• Explore /
  • Poster
  • / A randomized phase II study comparing oral S-1 plus 24-hour infusion of irinotecan (Iri) and bevacizumab (Bev) with FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer (MCRC).

A randomized phase II study comparing oral S-1 plus 24-hour infusion of irinotecan (Iri) and bevacizumab (Bev) with FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer (MCRC).

Abstract Poster

Authors

null

Sotaro Sadahiro

Tokai University, Kanagawa, Japan

Sotaro Sadahiro , Toshiyuki Suzuki , Akira Tanaka , Kazutake Okada , Gota Saito , Hiroshi Miyakita , Takashi Ogimi , Lin Fung Chan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

UMIN000014664

Citation

J Clin Oncol 37, 2019 (suppl 4; abstr 613)

DOI

10.1200/JCO.2019.37.4_suppl.613

Abstract #

613

Poster Bd #

J16

Abstract Disclosures

Similar Posters

First Author: Zev A. Wainberg

First Author: Zev A. Wainberg

First Author: M. Peeters

First Author: S. Stintzing